NCT02343549 2022-11-03
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
Phase 2 Terminated
Wake Forest University Health Sciences
Stanford University
H. Lee Moffitt Cancer Center and Research Institute